DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to Engage Medical Affairs

Engagement with Medical Affairs is critical at every juncture in the drug development process, with...
a-man-questioning-medical-device-regulatory-options

Which Regulatory Requirements Are Applicable to “Legacy” Devices?

Understanding the requirements for your medical device is vital in today’s market. But are these...
Medical device regulation and how the safety, performance, and RMS align

Simple Considerations before Determining S&P Objectives for Medical Devices

With all the things to consider with Medical Device Regulations, it's important to identify the...

MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)

An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Clinical Trial Pain Points

Pharma, Physician, and Patient Pain Points Regarding Clinical Trials

Pharma, physicians, and patients consistently face challenges related to clinical trials. Here's a quick look...

Learn more ABOUT our company.